MABS1865

Anti-4EBP2 Antibody, clone 16D9.1

clone 16D9.1, from mouse

• Synonym(e): Eukaryotic translation initiation factor 4E-binding protein 2, eIF4E-binding protein 2
• UNSPSC-Code: 12352203
• eCl@ss: 32160702
• NACRES: NA.41

Eigenschaften

• Biologische Quelle: mouse
• Antikörperform: purified immunoglobulin
• Antikörper-Produkttyp: primary antibodies
• Klon: 16D9.1, monoclonal
• Speziesreaktivität: human
• Speziesreaktivität (Voraussage durch Homologie): rat (based on 100% sequence homology), bovine (based on 100% sequence homology)
• Verpackung: antibody small pack of 25 μg
• Methode(n): immunohistochemistry: suitable (paraffin); western blot: suitable
• Isotyp: IgG1κ
• NCBI-Hinterlegungsnummer: NP_004087

Beschreibung

Allgemeine Beschreibung

Eukaryotic translation initiation factor 4E-binding protein 2 (UniProt: Q13542; also known as 4E-BP2, eIF4E-binding protein 2) is encoded by the EIF4EBP2 gene (Gene ID; 1979) in human. 4E-BP2 acts as a repressor of translation initiation involved in synaptic plasticity, learning and memory formation. However, insulin and other growth factors can release this inhibition via a phosphorylation-dependent disruption of their binding to eIF4E. 4E-BP2 regulates EIF4E activity by preventing its assembly into the eIF4F complex. 4E-BP2 undergoes phosphorylation at Threonine 37, 46, and 70 and Serine 65 and 83 by mTOR. 4E-BP2 contains a TOR signaling (TOS) motif (aa 116-120) that mediates interaction with RPTOR, leading to promote phosphorylation by mTORC1 complex. Its hypophosphorylated form competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repression of translation. On the other hand, hyperphosphorylated form of 4E-BP2 dissociates from EIF4E, which allows interaction between EIF4G1/EIF4G3 and EIF4E and leads to initiation of translation. 4E-BP2 is first phosphorylated at Threonine 37 and 46 by mTOR that induces folding of region from Proline 18 to Arginine 62 into a four-stranded beta-domain, which sequesters the helical YXXXXLPhi motif into a partly buried beta-strand that blocks accessibility to EIF4E. Protein phosphorylated at Threonine 37 and 46 is, however, unstable. Hence, subsequent phosphorylation at Serine 65 and 83 and Threonine 70 is required to stabilize the fold, which significantly reduces affinity for EIF4E. 4E-BP2 is enriched in brain where it acts as a regulator of synapse activity and neuronal stem cell renewal via its ability to repress translation initiation.

Spezifität

Clone 16D9.1 specifically detects eIF4E-binding protein 2 in human cells. It targets an epitope within 16 amino acids from the C-terminal region.

Immunogen

KLH-conjugated linear peptide corresponding to 16 amino acids from the C-terminal region of human eIF4E-binding protein 2.

Anwendung

Research Category
Zelluläre Signaltransduktion

Anti-4EBP2, clone 16D9.1, Cat. No. MABS1865, is a mouse monoclonal antobody that detects eIF4E-binding protein 2 and has been tested for use in Immunohistochemistry (Paraffin) and Western Blotting.

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected 4EBP2 in human pancreas and human liver tissue sections.

Qualität

Evaluated by Western Blotting in SHSY-5Y cell lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected 4EBP2 in SHSY-5Y cell lysate.

Zielbeschreibung

~13 kDa observed; 12.94 kDa calculated. Uncharacterized bands may be observed in some lysate(s).

Physikalische Form

Protein G purified

Format: Purified

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Lagerung und Haltbarkeit

Stable for 1 year at 2-8°C from date of receipt.

Sonstige Hinweise

Concentration: Please refer to lot specific datasheet.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.